<DOC>
	<DOCNO>NCT00162240</DOCNO>
	<brief_summary>A Phase 3 , Randomized , Double-blind , Placebo Controlled , Multicenter Trial Evaluate Safety Efficacy BMS-298585 Combination Metformin Therapy Subjects Type 2 Diabetes Who Have Inadequate Glycemic Control Metformin Therapy Alone</brief_summary>
	<brief_title>PPAR - Combination With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes HbA1c &gt; 7.0 % &lt; 10.0 % Mean serum triglyceride &lt; 600 mg/dL Body mass index &lt; 41 kg/m2 Fasting cpeptide &gt; 1.0 ng/mL History myocardial infarction ( MI ) coronary angioplasty bypass graft ( ) valvular disease repair unstable angina pectoris transient ischemic attack ( TIA ) , cerebrovascular attack , cerebrovascular accident ( CVA ) within 6 month Congestive heart failure NYHA Class III IV Uncontrolled hypertension History renal disease , peripheral vascular disease ( PVD ) , pulmonary disease , gastrointestinal disease , active liver disease endocrine disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Metabolics Diabetes New Onset</keyword>
</DOC>